279. Huge venous malformation with cervical, oral and pharyngeal diffuse lesion Clinical trials / Disease details
Clinical trials : 15 / Drugs : 24 - (DrugBank : 10) / Drug target genes : 3 - Drug target pathways : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCT2051200046 | 15/01/2021 | 25/08/2020 | A study for evaluation of efficacy and safety of ethanolamine oleate in patients with venous malformations | Evaluation of efficacy and safety of ethanolamine oleate in sclerotherapy in patients with venous malformations: A multicenter, open-label, single-arm study - EO-1 | Venous malformation difficult to remove | Injection of 5% ethanolamine oleate which is double diluted by contrast or normal saline for the venous malformation, within maximum dosage of 0.4 mL/kg. Same method of administration is performed for children. Maximum volume of the drug in once treatment is 30 mL after preparation. | Nomura Tadashi | Nomura Tadashi;Ozaki Mine | Recruiting | Not applicable | Not applicable | Both | 44 | Phase 3 | Japan |
| 2 | NCT04930952 (ClinicalTrials.gov) | February 28, 2019 | 11/6/2021 | Complications of Ethanol-amine Oleate Intralesional Sclerotherapy | Complications of Ethanol-amine Oleate Intralesional Sclerotherapy Injections of Maxillofacial Venous Malformations in Pediatric Patients | Venous Malformation | Drug: Ethanol-amine Oleate Sclerotherapy Injection | Suez Canal University | NULL | Completed | N/A | 12 Years | All | 15 | Egypt | |
| 3 | ChiCTR-OIB-15007455 | 2015-03-18 | 2015-11-24 | Effect of sclerotherapy on venous malformation associated with localized intravascular coagulopathy: A prospective, before-after controlled study | Effect of sclerotherapy on venous malformation associated with localized intravascular coagulopathy: A prospective, before-after controlled study | venous malformation | 1:sclerotherapy with ethanol; | Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine | NULL | Recruiting | Both | 1:40; | I (Phase 1 study) | China | ||
| 4 | JPRN-jRCTs071180067 | 23/10/2009 | 20/03/2019 | Clinical research of intralesional sclerotherapy in the oral and maxillofacial region | Clinical research for safty and efficacy in intralesional sclerotherapy with ethanolamine oleate for subcutaneous venous malformation in the oral and maxillofacial region - EOST-OMS | Venous malformation in the oral and maxillofacial region Sclerotherapy, Venous malformation, ethanolamine oleate;angioma, venous | Single arm study, open (masking not used), no assignment All procedures will be done with oral surgeon and radiologist in angiography room. (For superficial lesion, procedures will be done with intermittent simple X-ray for reduction of exposure, despite using angiography to confirm drainage veins in oral and maxillofacial outpatient clinic.) 1. Local anesthesia into the lesion. 2. Puncture with 22-24G needle and confirm the backflow of blood. 3. Stabilize the needle and check the distribution and blood flow of the lesion by angiography and computed tomography (CT) with contrast medium. If there is any risk that sclerosing agent will escape whole body, we must decide the cancellation of the trial. If we can block the drainage vein over 5 minutes, we decide that the trial can continue. (For superficial lesions, we inject contrast medium in oral and maxillofacial outpatient clinic and confirm retention of contrast medium using intermittent simple X-ray.) 4. Treat with injection 5% ethanolamine oleate(EO) (diluted by Iopamiron 300) . Volume of the 5%EO will be decided by situation, but the maximum volume is 20ml (5% EO) by one treatment. After 5 minites, the 5%EO collect as possible. 5. Check the hemostasis of the injection point(s). | Danjo Atsushi | NULL | Recruiting | Not applicable | Not applicable | Both | 25 | Phase 2 | Japan |
| 5 | EUCTR2009-011276-29-FR (EUCTR) | 21/08/2009 | 15/05/2009 | Systemic and local diffusion of ethanol after administration of ethanol 96% formulated in a gel (L0122 Gel) and ethanol 98% solution (absolute ethanol) by the percutaneous route, in patients with congenital venous malformations (CVM): pharmacokinetic, pharmacodynamic and clinical study. | Systemic and local diffusion of ethanol after administration of ethanol 96% formulated in a gel (L0122 Gel) and ethanol 98% solution (absolute ethanol) by the percutaneous route, in patients with congenital venous malformations (CVM): pharmacokinetic, pharmacodynamic and clinical study. | patients with congenital venous malformations (CVM) | Product Name: Ethanol gel Product Code: L0122 Other descriptive name: ETHANOL (96 PER CENT) Trade Name: Dehydrated Alcohol (Absolute Alcohol) BP for Injection Product Name: Dehydrated Alcohol (Absolute Alcohol) BP for Injection Other descriptive name: ETHANOL BP | ORFAGEN | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | France | ||
| 6 | NCT00462462 (ClinicalTrials.gov) | May 2007 | 16/4/2007 | Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study. | Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study. | Congenital Venous Malformation | Drug: Ethanol 96% Gel;Drug: Ethanol 98% Solution | Orfagen | FDA Office of Orphan Products Development | Completed | 12 Years | N/A | All | 32 | Phase 2 | United States;France |